News Release 

IVI-SK's new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal

Primary analysis also confirms safety of Vi-DT

International Vaccine Institute

Science Business Announcement

December 17, 2020 - SEOUL, South Korea - Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary endpoints were based on immune non-inferiority with the WHO-prequalified typhoid conjugate vaccine, Typbar-TCV®, in terms of serconversion rate, which confirms the new candidate TCV induces an immune response that is not inferior to Typbar-TCV®.

Three different production lots of vaccine were administered in the clinical trial, and the analysis also shows that these different batches were similar in immunogenicity. Lot-to-lot consistency in manufacturing is an important requirement to ensure the quality of Vi-DT.

In addition to immune non-inferiority, the Vi-DT vaccine was also shown to be safe in all 1,350 participants ranging in age from 6 months to 45 years.

This study is a significant milestone in an effort to license Vi-DT TCV. Another phase III study is nearing completion in the Philippines and SK bioscience plans to submit a Marketing Authorization request to the Korean Ministry of Food & Drug Safety in January 2021. After the Ministry of Food and Drug Safety approves the vaccine, it will be submitted for pre-qualification review at the World Health Organization. WHO pre-qualification is necessary for a vaccine to be sold to United Nations agencies responsible for vaccine purchases.

"It was a challenging project to get the sites in Nepal ready," said Dr. Tarun Saluja, MD, the project lead of this study. "However, with the help of the authorities in Nepal and our collaborators, we managed to complete this study within timeline and with quality."

"These data are the culmination of 10 years of work at IVI," said Dr. Sushant Sahastrabuddhe, MD, Director of IVI's Typhoid Program. "With the successful initial results from phase I and II studies in the Philippines, this phase III study was critical to make sure Vi-DT vaccine completes the regulatory milestones for use in endemic countries. We are quite pleased with the results and plan to publish them soon."

"With this encouraging data from the Phase 3 trial, we have taken a step closer to the commercialization of the vaccine," said Jae-yong Ahn, CEO of SK bioscience. "In collaboration with IVI and other partners, we will develop a vaccine that is universally accessible to help free children in developing countries from typhoid."

Vi-DT was developed at IVI and its technology was transferred in 2013 to SK bioscience in South Korea for manufacturing and commercialization. A Phase I safety trial of Vi-DT was first conducted in the Philippines in volunteers aged 2-45 years and showed that the vaccine was safe and immunogenic four weeks after first dose. Following the successful completion of a Phase II trial with infants under 2 years, large-scale Phase III studies with a single-dose of Vi-DT started in the Philippines and Nepal this year.

###

About typhoid

Typhoid fever is an invasive water-borne bacterial infection caused by Salmonella enterica serovar Typhi (S. Typhi) presenting with mild to severe symptoms and even resulting in death. Typhoid is most often contracted through ingestion of food or drink contaminated by bacteria shed by infected people. It is usually characterized by fever, headache, constipation, and malaise, though diagnosis can be difficult due to symptoms common to other febrile illnesses. Figures for burden of disease vary due to this difficulty, however the World Health Organization estimates that 128,000-161,000 people die every year from typhoid fever with 11-21 million annual cases. (1) Typhoid surveillance studies report that a quarter to more than half of all invasive cases are found in children under 5. (2)

(1) https://apps.who.int/iris/bitstream/handle/10665/272272/WER9313.pdf?ua=1

(2) J A Crump, E D Mintz Global trends in typhoid and paratyphoid Fever. ClinInfect Dis 2010;50(2):241-246.

About the International Vaccine Institute (IVI)

The International Vaccine Institute (IVI) is a nonprofit inter-governmental organization established in 1997 at the initiative of the United Nations Development Programme (UNDP). Headquartered in Seoul, South Korea, IVI was the first international organization hosted by Korea. IVI has 36 signatory countries and the World Health Organization (WHO) on its treaty, including Korea, Sweden, India, and Finland as state funders.

Our mandate is to make vaccines available and accessible for the world's most vulnerable people. We focus on infectious diseases of global health importance such as cholera, typhoid, shigella, salmonella, schistosomiasis, chikungunya, group A strep, Hepatitis A, HPV, TB, HIV, MERS, COVID-19, as well as antimicrobial resistance. For more information, please visit https://www.ivi.int

CONTACT

Aerie Em, Global Media & Communications Specialist +82 2 881 1386 | aerie.em@ivi.int

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.